BioLine RX Stock

BioLine RX Market capitalization

The The market capitalization of BioLine RX (BLRX.TA) as of Mar 19, 2026 is 576.59 M USD.In the previous year, The market capitalization was 605.8 M USD — a change of -4.82% (lower).

Market capitalization

576.59 MUSD

YoY

-4.82%

Last updated:

In 2026, BioLine RX's market cap stood at 576.59 M USD, a -4.82% increase from the 605.8 M USD market cap in the previous year.

The BioLine RX Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Capitalization (B USD)
Date
Market Capitalization (B USD)
Jan 1, 2005
0 base
Jan 1, 2006
0 base
Jan 1, 2007
8.93 base
Jan 1, 2008
5.02 base
Jan 1, 2009
8.25 base
Jan 1, 2010
14.65 base
Jan 1, 2011
7.32 base
Jan 1, 2012
6 base
Jan 1, 2013
6.52 base
Jan 1, 2014
7.53 base
Jan 1, 2015
11.67 base
Jan 1, 2016
6.79 base
Jan 1, 2017
10.54 base
Jan 1, 2018
11.27 base
Jan 1, 2019
5.5 base
YEARMarket Capitalization (B USD)
2024 0.58
2023 9.95
2022 7.54
2021 13.31
2020 3.65
2019 5.5
2018 11.27
2017 10.54
2016 6.79
2015 11.67
2014 7.53
2013 6.52
2012 6
2011 7.32
2010 14.65
2009 8.25
2008 5.02
2007 8.93
2006 -
2005 -
Access this data via the Eulerpool API

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring BioLine RX's Market Capitalization

BioLine RX's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of BioLine RX's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

BioLine RX's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in BioLine RX’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about BioLine RX stock

The market capitalization of BioLine RX amounted to 605.8 M USD 576.59 M

Access this data via the Eulerpool API

Valuation — BioLine RX

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

All Key Metrics — BioLine RX